Upon inhalation it uses the patient’s breath to disperse the dry powder formulation into small particles appropriately sized for deep lung deposition. Cyclops™ has several advantages compared to standard-of-care DPIs across key therapeutic areas. These attributes enable the hygienic and effective use on a worldwide scale. One product, Colistin Cyclops™, is already available to patients and reimbursed under a named patient regimen for the treatment of cystic fibrosis.

Single- and multi-use versions of Cyclops™ are available.